-

06:12:26 AM

Latest APDN Stock Market News

APDN - Applied Dna Sciences Inc

06/08/21 9:00 AM

Nasdaq : APDN

Applied DNA Sciences and A&E Introduce Anti-Counterfeiting Technology for Sustainable Sewing Threads

Applied DNA Sciences, Inc. (NASDAQ: APDN), a leader in Polymerase Chain Reaction (PCR)-based DNA manufacturing, and American & Efird, (A&E), the world’s foremost thread manufacturer, today announced A&E’s INTEGRITY™ advanced identification thread technology is available for its ECO100 recycled

RHEA-AI

neutral

06/07/21 9:00 AM

Nasdaq : APDN

Applied DNA Reports Veterinary COVID-19 Vaccine Candidate Induces Neutralizing Antibodies in 100% of Trial Cohort Against B.1.1.7, P1, and B.1.526 Variants and Sets August 2021 Mink Challenge Trial Launch

Applied DNA Sciences, Inc. (NASDAQ: APDN) (Applied DNA or the “Company”), a leader in Polymerase Chain Reaction (PCR)-based DNA manufacturing, and its program development partner, Evvivax, S.R.L. (“Evvivax”), today announced results from an in vitro neutralization study of sera from the trial

RHEA-AI

very negative

06/02/21 9:00 AM

Nasdaq : APDN

Applied DNA Adds First Summer Camp for safeCircle Pooled COVID-19 Surveillance Testing

Applied DNA Sciences, Inc. (NASDAQ: APDN) (Applied DNA or the “Company”), a leader in Polymerase Chain Reaction (PCR)-based DNA manufacturing, today announced that its wholly-owned subsidiary, Applied DNA Clinical Labs, LLC (ADCL), has secured a safeCircle™ pooled COVID-19 surveillance testing

RHEA-AI

neutral

05/26/21 8:00 AM

Nasdaq : APDN

Applied DNA Completes Technical Validation of PCR-based SARS-CoV-2 Mutation-Detection Panel, Highlights Ability to Rapidly Identify Mutations and Probable Variants

Applied DNA Sciences, Inc. (NASDAQ: APDN) (Applied DNA or the “Company”), a leader in Polymerase Chain Reaction (PCR)-based DNA manufacturing, today announced that it has competed technical validation of all seven Research Use Only (RUO) mutation detection assays contained in its Linea™ COVID-19

RHEA-AI

neutral

05/13/21 9:51 PM

Nasdaq : APDN

Applied DNA Provides Clarification on Newly Authorized Asymptomatic Serial Screening Indication for LineaTM COVID-19 Assay Kit and Press Release Published 12 May 2021

Applied DNA Sciences, Inc. (NASDAQ: APDN) (Applied DNA or the “Company”), today clarifies the scope of its newly authorized asymptomatic serial screening indication for its Linea COVID-19 Assay Kit (the “Assay Kit”) and certain information contained in its previously disseminated 12 May 2021 press

RHEA-AI

neutral

05/13/21 4:10 PM

Nasdaq : APDN

Applied DNA Second Fiscal Quarter 2021 Financial Results Feature 384% Year-Over-Year Growth in Revenues

Applied DNA Sciences, Inc. (NASDAQ: APDN) (the “Company”), a leader in Polymerase Chain Reaction (PCR)-based DNA manufacturing, today announced consolidated financial results for the three and six months ended March 31, 2021.“We are pleased to deliver a strong fiscal second quarter with

RHEA-AI

positive

05/12/21 9:35 AM

Nasdaq : APDN

FDA Grants EUA to Applied DNA LineaTM COVID-19 Assay Kit for Asymptomatic Screening of Individuals with Serial Testing

Applied DNA Sciences, Inc. (NASDAQ: APDN) (Applied DNA or the “Company”), a leader in Polymerase Chain Reaction (PCR)-based DNA manufacturing, today announced that the U.S. Food and Drug Administration (FDA) has granted the Company’s Linea™ COVID-19 Assay Kit (the “Assay Kit”) a re-issued Emergency

RHEA-AI

neutral

05/11/21 9:15 AM

Nasdaq : APDN

Applied DNA Receives CLIA Certification, Enabling High Throughput Diagnostic COVID-19 Testing

Applied DNA Sciences, Inc. (NASDAQ: APDN) (Applied DNA or the “Company”), a leader in Polymerase Chain Reaction (PCR)-based DNA manufacturing, today announced that its Applied DNA Clinical Labs, LLC (ADCL) subsidiary received CLIA (Clinical Laboratory Improvement Amendments) certification from the

RHEA-AI

neutral

05/07/21 10:00 AM

Nasdaq : APDN

Applied DNA Schedules Fiscal 2021 Second Quarter Financial Results Conference Call and Webcast for Thursday, May 13, 2021

Applied DNA Sciences, Inc. (NASDAQ: APDN) (“Applied DNA” or the “Company”), a leader in Polymerase Chain Reaction (PCR)-based DNA manufacturing, today announced that it will report fiscal 2021 second quarter financial results after market close on Thursday, May 13, 2021. The Company’s management

RHEA-AI

neutral

05/06/21 8:00 AM

Nasdaq : APDN

Applied DNA and Evvivax Announce that LinearDNA™ COVID-19 Vaccine Candidate Booster Yields 5-Fold Average Increase in Neutralizing Antibody Titers in Domestic Felines

Applied DNA Sciences, Inc. (NASDAQ: APDN) (Applied DNA or the “Company”), a leader in Polymerase Chain Reaction (PCR)-based DNA manufacturing, and its program development partner, Evvivax, S.R.L. (“Evvivax”), today announced a booster injection delivered 30 days after the prime vaccination elicited

RHEA-AI

positive

1 2 3 4 5 6 Next

APDN Data

industryCyclic Crude, Intermediate, and Gum and Wood Chemical Manufacturing
websitehttps://adnas.com
ceoJames Hayward
security nameApplied Dna Sciences Inc
issue typecs
sectorManufacturing
sic code2865
employees
tagsManufacturing,Technology Services,Cyclic Crude, Intermediate, and Gum and Wood Chemical Manufacturing ,Health Technology,Pharmaceuticals: Major,Miscellaneous Commercial Services,Commercial Services,Information Technology Services
address50 Health Sciences Dr
address2
stateNew York
cityStony Brook
zip11790-3349
countryUS
phone16312408800

APDN Description:

Applied DNA is commercializing LinearDNA™, its proprietary, large-scale polymerase chain reaction ('PCR')-based manufacturing platform that allows for the large-scale production of specific DNA sequences. The LinearDNA platform has utility in the nucleic acid-based in vitro diagnostics and preclinical nucleic acid-based drug development and manufacturing market. The platform is used to manufacture DNA for customers as components of in vitro diagnostic tests and for preclinical nucleic acid-based drug development in the fields of adoptive cell therapies (CAR T and TCR therapies), DNA vaccines (anti-viral and cancer), RNA therapies, clustered regularly interspaced short palindromic repeats (CRISPR) based therapies, and gene therapies. Applied DNA has also established a COVID-19 diagnostic and testing offering that is in the early stages of commercialization and is grounded in the Company's deep expertise in DNA. The LinearDNA platform also has non-biologic applications, such as supply chain security, anti-counterfeiting and anti-theft technology. Key end-markets include textiles, pharmaceuticals and nutraceuticals, and cannabis, among others.